C4 Therapeutics (Series A)
Funding Details
- Awarder
- Inbox
- Date Award
- January 07, 2016
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $73,000,000
Company Info
- Founders
- Jason Fisherman, MD
- Company Description
- C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. Their Degronimid platform incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS).
- Market
- Pharmaceuticals
- Location
- Cambridge, MA, USA
- Coinvestors
- Cobro Ventures, Cormorant Asset Management, EG Capital Group, Novartis Venture Funds, Roche Venture Fund, The Kraft Group